Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PEG-aldesleukin
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
PEG-aldesleukin is a pegylated formulation of recombinant human interleukin-2 (aldesleukin), originally developed by Chiron Corporation. Interleukin-2 is a potent cytokine that plays a central role in the immune system by stimulating the proliferation and activation of T-lymphocytes and natural killer (NK) cells. The addition of polyethylene glycol (PEG) chains to the IL-2 molecule (pegylation) is designed to increase its hydrodynamic size, thereby reducing renal clearance and significantly extending its biological half-life compared to the non-pegylated form. In the 1990s, PEG-aldesleukin was investigated as an immunomodulatory adjunct to antiretroviral therapy (such as zidovudine or didanosine) in patients with HIV infection. The therapeutic goal was to restore immune function by expanding CD4+ T-cell populations. While clinical trials demonstrated the ability of the drug to increase CD4+ counts, development for the HIV indication was eventually discontinued by Chiron.
- Other names
- Polyethylene glycolated interleukin-2PEG-interleukin-2PEG-interleukin2PEG-interleukin 2Pegylated IL-2PEG-IL2PEG-IL-2PEG-IL 2
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on PEG-aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PEG-aldesleukin.